BioCryst Pharmaceuticals Newsroom

BioCryst and the Pan-Canadian Pharmaceutical Alliance (PCPA) Successfully Complete Negotiations for ORLADEYO (Berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

GlobeNewswireSep 17 19:00

BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals

Yahoo FinanceSep 12 13:25

Island Pharmaceuticals Signs Letteer of Intent to Acquire BioCryst's Antiviral Program

MT NewswiresSep 11 12:02

BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium

BenzingaSep 6 15:02

BioCryst Presents New ORLADEYO (Berotralstat) Data at 7th Bradykinin Symposium

GlobeNewswireSep 6 14:00

Express News | BioCryst Appoints DR. Donald Fong Chief Medical Officer

BreakingsSep 5 19:00

Press Release: BioCryst Appoints Dr. Donald Fong Chief Medical Officer

Dow JonesSep 5 19:00

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireSep 4 19:00

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 7.3% Over the Past Week

Simply Wall StSep 1 20:56

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswireAug 22 19:00

'Bottom-fishing' Ideas Within Piper Sandler's Universe of Stocks

Seeking AlphaAug 20 23:56

Piper Lists Eight Defensive Biotechs to Face Market Volatility

Seeking AlphaAug 11 02:29

Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10

Evercore analyst Liisa Bayko maintains $BioCryst Pharmaceuticals(BCRX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 45.6%

Futu NewsAug 7 12:32 · Ratings

BioCryst Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

SECAug 7 04:09 · Announcements

JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $16

BenzingaAug 7 01:04 · Ratings

BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays

Dow JonesAug 6 21:03

BioCryst Pharmaceuticals Price Target Raised to $7.00/Share From $6.00 by Barclays

Dow JonesAug 6 21:03 · Ratings

A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30

On Aug 06, major Wall Street analysts update their ratings for $BioCryst Pharmaceuticals(BCRX.US)$, with price targets ranging from $10 to $30.Evercore analyst Liisa Bayko maintains with a buy rating,

Futu NewsAug 6 21:00 · Ratings

BioCryst Pharmaceuticals: A Buy Rating Anchored on Orladeyo's Success and Expansion in Rare Disease Treatments

TipRanksAug 6 18:35 · Ratings

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

BenzingaAug 6 18:30 · Ratings